Voting Rights

Ardana PLC
28 February 2007


Ardana plc (LSE: ARA) - voting rights and capital



Edinburgh, UK, 28 February 2007; In conformity with the Transparency Directive's
transitional provision 6 we would like to notify the market of the following:



As at 28 February 2007, the issued share capital and voting rights of Ardana plc
are as follows:



Ardana plc's capital consists of 65,511,729 ordinary 1p shares with voting
rights attached of one vote per ordinary share of which 12,681 ordinary shares
are held in Treasury.



Therefore, the total number of voting rights in Ardana plc is 65,499,048.



The above figure (65,499,048) may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Ardana plc under the FSA's
Disclosure and Transparency Rules.



Enquiries



For more information contact:


Maureen Lindsay                                            + 44 (0) 131 226 8550
Ardana

Julia Phillips/John Gilbert                                  [phone]
Financial Dynamics
(corporate and financial media relations)



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market*.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.



Ardana's four lead products are summarised below:



  • Emselex(R), a once a day treatment for the symptoms of overactive bladder
    which Ardana has exclusive UK marketing and promotion rights and is being
    distributed in collaboration with Novartis Pharmaceuticals UK Limited;

  • StriantTM SR, a testosterone replacement therapy that has been launched by
    Ardana through its own sales force in the UK and through marketing partners
    in certain European countries, as a treatment for men with confirmed
    hypogonadism;

  • Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe;

  • Teverelix LA, in development for three initial indications (prostate
    cancer, BPH and endometriosis);

  • Testosterone Cream, a transdermal testosterone delivery system in
    development for the treatment of male hypogonadism, in Phase II trials; and

  • Oral GHS (EP01572) a oral growth hormone secretagogue in late stage
    development in the first indication for the diagnosis of growth hormone
    deficiency and in early stage development in a second indication.



In addition, Ardana has a strong portfolio of follow-on products in development.



Ardana is listed on the Main Market of the London Stock Exchange.



For further information please see www.ardana.co.uk



*Source: IMS Retail Drug Monitor November 2005.





Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements. In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'. Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.


                      This information is provided by RNS
            The company news service from the London Stock Exchange